Tag Archives: ARWR
A Director at Arrowhead Pharmaceuticals is Exercising Options
Yesterday it was reported that a Director at Arrowhead Pharmaceuticals (ARWR – Research Report), Michael S. Perry, exercised options to buy 77,000 ARWR shares at $3.70 a share, for a total transaction value of $285.2K. Following Michael S. Perry’s last
Cantor Fitzgerald Remains a Buy on Arrowhead Pharmaceuticals (ARWR)
Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $58.00. The company’s shares closed last Thursday at $35.13. According to TipRanks.com, Young is a 5-star analyst
Thursday’s Midday Movers: Ebix (EBIX), Omega Healthcare (OHI), Nu Skin (NUS), El Pollo LoCo (LOCO), Arrowhead Pharmaceuticals (ARWR)
So far Thursday, March 19, NASDAQ is up 12.04% and the S&P is up 3.46%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Ebix (EBIX – Research Report), Omega Healthcare (OHI – Research
B.Riley FBR Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $57.00. The company’s shares closed last Monday at $26.32, close to its
The CFO of Arrowhead Pharmaceuticals is Exercising Options
Yesterday it was reported that the CFO of Arrowhead Pharmaceuticals (ARWR – Research Report), Kenneth Allen Myszkowski, exercised options to buy 43,445 ARWR shares at $8.84 a share, for a total transaction value of $384.1K. This recent transaction increases Kenneth
Monday’s Highlights at Noon: Second Sight Medical Products (EYES), Novavax (NVAX), Rite Aid (RAD), Arrowhead Research (ARWR), Pacira Pharmaceuticals (PCRX)
So far Monday, February 10, NASDAQ is up 2.58% and the S&P is up 1.86%. Here are this morning’s most active stocks: Second Sight Medical Products (EYES – Research Report), Novavax (NVAX – Research Report), Rite Aid (RAD – Research
